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Abstract
Background: The aim was to retrospectively assess the results of treatment of upper urinary tract stones with the
Sonolith vision manufactured by EDAP, and purchased in 2004.
Methods: The subjects were 226 Japanese patients who underwent extracorporeal shock wave lithotripsy (ESWL)
alone as an initial treatment and could be followed up for at least 3 months, selected from 277 candidate patients
who underwent this therapy between 2004 and 2006. Treatment effect was evaluated by kidney, ureter, and
bladder X-ray or renal ultrasonography at 1 and 3 months after treatment. A stone-free status or status of stone
fragmentation to 4 mm or smaller was considered to indicate effective treatment.
Results: At 3 months after treatment, the stone-free rate was 69.4% and the efficacy rate was 77.4% for renal
stones, while these rates were 91.5 and 93.3%, respectively for ureteral stones. Assessment of treatment effect
classified by the location of stones revealed a stone-free rate of 94.6% and an efficacy rate of 94.6% for lower
ureteral stones (4.0 mm or smaller, 1 subject; 4.1-10.0 mm, 31 subjects; 10.1-20.0 mm, 5 subjects: number of
treatment sessions, 1 or 2 sessions [mean: 1.03 sessions]). Complications of this therapy included renal subcapsular
hematoma and pyelonephritis in 1 case each.
Conclusions: ESWL with the Sonolith vision manufactured by EDAP produced a treatment effect equivalent to
those achieved with other models of ESWL equipment. ESWL seems to be an effective first-line treatment also in
patients who have lower ureteral stones 10 mm or larger but do not wish to undergo TUL, if measures such as
suitable positioning of the patient during treatment are taken.
Background
Extracorporeal shock wave lithotripsy (ESWL) was
introduced in clinical practice by Chaussy et al. in the
1980 s [1]. Its usefulness is widely recognized, and it has
become the most common treatment for upper urinary
tract stones. ESWL has been performed more frequently
than TUL for stone treatment in Japan compared with
that in Europe and the United States (2008 General
Meeting, Seminar of the Japanese Urological Associa-
tion), which may be largely attributable to its simplicity
and/or the National Health Insurance System in Japan.
Our hospital introduced the Sonolith vision (manufac-
tured by EDAP) in March 2004 in place of the old
equipment, and has been performing ESWL on patients
with upper urinary tract stones. Here we report the
favorable results of treatment of lower ureteral stones in
cases where lithotripsy was difficult, which were
achieved by putting the patient in a suitable position.
Methods
T h ep r e s e n ts t u d yw a sr e v i e w e da n da p p r o v e db yt h e
Ethics Committee of Aichi Medical University School of
Medicine (No. 11-015). The subjects were 226 Japanese
patients who underwent ESWL alone and could be
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candidate patients who underwent this therapy as the
initial treatment between March 1, 2004 and December
31, 2006. The subjects included 169 male and 57 female
aged from 17 to 86 years (mean: 50.5 years). The stones
were on the left side in 128 subjects and on the right
side in 98. The locations and sizes of the stones are
shown in Table 1.
Treatment was performed during a hospital stay of
three days and two nights, and the subjects were only
fasted before operation. Preoperative medication
included diclofenac suppository, Atarax-P, atropine sul-
fate (i.m.), and glycerin enema (60 mL). When subjects
complained of severe pain during operation, pentazocine
(i.m.) was additionally administered. Renal stones were
treated at a maximum energy level of 80%, while uret-
eral stones were treated at a level of 100%. Both renal
and ureteral stones were treated with up to 3000 shock
waves. Treatment effect was evaluated by kidney, ureter,
and bladder (KUB) X-ray or intravenous pyelography at
1 and 3 months after operation, and was classified as
stone-free status (absence of residual stones), effective
(presence of residual stones 4 mm or smaller), inade-
quate (status other than the above), or ineffective (no
stone fragmentation even after 2 treatment sessions of
ESWL).
Treatment was completed if an effective or better
response was demonstrated by KUB on the day after the
operation. If stone fragmentation was found to be inade-
quate, a second ESWL session was performed after
about 1 to 4 weeks. If any stone fragmentation was
achieved, third and subsequent ESWL sessions were
performed. Subjects with an inadequate or no response
(ineffective) to ESWL underwent transurethral uretero-
lithotripsy (TUL) or percutaneous nephrolithotripsy
(PNL). Subjects with urinary tract infection or with
stones 20 mm or larger underwent placement of a dou-
ble-J stent. During the procedure, subjects with renal or
upper ureteral stones were placed in the ipsilateral
supine position, those with middle ureteral stones in the
ipsilateral prone position, and those with lower ureteral
stones in the contralateral prone position (Figure 1).
Subjects with X-ray-negative stones underwent intrave-
nous pyelography (IVP) and ureteral catheter insertion
in combination with ESWL.
Results
Of the 226 cases, 30 cases underwent placement of a
ureteral stent and 14 cases underwent IVP. When the
stones were classified by location, middle renal stones
were the most frequent (52 cases) among subjects with
renal stones, while upper ureteral stones (113 cases)
were the most frequent among subjects with ureteral
stones. When the stones were classified by size, those
10.1 - 20.0 mm were the most frequent (43 cases) of
renal stones, while those 4.1 - 10.0 mm were the most
frequent (119 cases) of ureteral stones. One to 10 treat-
ment sessions (mean: 1.62 sessions) were performed.
Renal stones were treated with a mean of 1.8 sessions,
of which middle renal stones of 20.1 mm or larger were
treated with the largest number of sessions (mean: 3.9
sessions). Ureteral stones were treated with a mean of
1.44 sessions, of which middle ureteral stones of 10.1 -
20.0 mm or larger were treated with the largest number
of sessions (mean: 3.6 sessions) (Table 2). One month
after operation, the stone-free rate was 48.4% and the
efficacy rate was 64.5% for renal stones, while these
rates were 70.7 and 80.5%, respectively for ureteral
stones. Three months after operation, the stone-free rate
was 69.4% and the efficacy rate was 77.4% for renal
stones, while these rates were 91.5 and 93.3%, respec-
tively for ureteral stones. When the treatment effect was
analyzed by the location of stones, a stone-free rate of
94.6% and an efficacy rate of 94.6% were achieved in
subjects with lower ureteral stones (≤ 4.0 mm, 1 subject;
4.1 - 10.0 mm, 31 subjects; 10.1 - 20.0 mm, 5 subjects)
with one or two ESWL treatment sessions (mean: 1.03
sessions) at three months after operation (Table 3). All
five subjects with stones 10 mm or larger achieved a
complete stone-free status.
Fourteen subjects with X-ray-negative stones under-
went intravenous pyelography (IVP) and ureteral cathe-
ter insertion in combination with ESWL. These patients
had a stone-free status with only ESWL therapy.
Of the 25 cases in whom ESWL was ineffective, 8
cases were confirmed to be stone free three or more
months after operation, while 7 cases with residual
stones were followed up because hydronephrosis
improved. Of the subjects with upper ureteral stones in
whom ESWL was ineffective, 7 cases underwent TUL
and 2 cases underwent PNL. One case with concomitant
ureteral stenosis underwent holmium laser incision fol-
lowing stone fragmentation with TUL.
The chemical composition of stones could be deter-
mined in 128 cases. Calcium oxalate stones were the
Table 1 Location and size of stones
≤ 4.0
mm
4.1-10.0
mm
10.1-20.0
mm
≥ 20.1
mm
Total
(n)
Middle renal 5 36 11 52
Lower renal 2 7 1 10
Upper
ureteral
77 35 1 113
Middle
ureteral
11 3 14
Lower
ureteral
13 1 5 3 7
Total (n) 1 126 86 13 226
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Page 2 of 5most frequent (68 cases), followed by mixed calcium
oxalate and calcium phosphate stones (49 cases), and
stones containing calcium were present in 126 cases.
All subjects experienced postoperative gross hematuria
as a complication. One case developed renal subcapsular
hematoma which improved with conservative treatment.
One case developed fever of 38°C or higher, which
resolved with antibiotic therapy. Fifteen subjects
required pentazocine for pain during the operative
procedure.
Discussion
Since Chaussy et al. [1] reported the application of
ESWL with an HM-3 lithotriptor manufactured by Dor-
nier Co., Ltd. in clinical practice in the 1980 s, various
models of ESWL equipment have been developed and
improved. Shock wave generators have been developed,
starting with the underwater spark gap type, followed by
the electromagnetic conversion type and the piezoelec-
tric element type. ESWL is now the first-line treatment
for upper urinary tract stones.
Our hospital introduced the Sonolith vision (manufac-
tured by EDAP) on March 1, 2004. This model belongs
to third generation ESWL equipment. It uses electrical
conduction electrodes as the shock wave generator,
which generates shock waves in a highly electrical-con-
ductive fluid. It provides accurate electrical discharge
with high reproducibility, thus producing stable and
constant energy. The use of a hydrophone pressure
detector allows real-time display of the effective pressure
of shock waves on a monitor. The generator is a shallow
oval shape, and the output power can be adjusted to 100
different levels. The diameter of the shock-wave head is
as large as 22 cm, and the consumptive electrodes can
be used in four to five patients. This equipment has a
focal depth of 130 mm and a focal size of 3 × 28 mm.
The focal point is adjusted using an X-ray C-arm.
In 226 Japanese cases with renal or ureteral stones
who were treated with ESWL in our hospital, the stone-
free rate was 85.4% and the efficacy rate was 88.9%,
showing similar results to those obtained by other
researchers [2-5]. (Table 4).
With regard to lower ureteral stones, Hochreiter et al.
[6] treated distal ureteral stones with the HM-3 litho-
triptor manufactured by Dornier in 518 patients, and
reported a stone-free rate of 97.3% and efficacy rate of
99.4%. Park et al. [7], however, reported that the stone-
free rate was 55.6% for lower ureteral stones of 10 mm
Figure 1 A) ESWL approaches to middle ureteral stones. (Ipsilateral prone position). B) ESWL approaches to lower ureteral stones.
(Contralateral prone position)
Table 2 Location and size stones and number of
treatment
Number of
treatment sessions
Mean
(session)
1 2 3 461 0
4.1-10.0 mm 4 1 1.2
Middle renal 10.1-20.0
mm
20 9 3 4 1.8
≥ 20.1 mm 1 1 4 3 1 1 3.9
4.1-10.0 mm 2 1
Lower renal 10.1-20.0
mm
3 3 1 2.1
≥ 20.1 mm 1 1
4.1-10.0 mm 66 9 2 1.2
Upper ureteral 10.1-20.0
mm
28 5 2 1.3
≥ 20.1 mm 1 1
4.1-10.0 mm 10 1 1.2
Middle
ureteral
10.1-20.0
mm
1 1 1 3.6
4.1-10.0 mm 1 1
Lower ureteral 10.1-20.0
mm
31 1
≥ 20.1 mm 4 1 1.2
Total(n) 172 30 13 7 3 1 1.62
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Page 3 of 5or larger. Pardalidis et al. [8] also reported that treat-
ment was not so effective, with a stone-free rate of
84.6%. Ghalayini et al. [10] compared laser TUL with
ESWL, and reported that laser TUL was significantly
m o r ee f f e c t i v et h a nE S W L ,w i t has t o n e - f r e er a t eo f
97.5% vs. 81.5% three months after operation. Wu et al.
[11] compared holmium yttrium-aluminum-garnet
(YAG) laser TUL with ESWL in patients with upper
ureteral stones, and reported that there was no signifi-
cant difference in the treatment effect on stones 10 mm
or smaller, with a stone-free rate of 91.1% for TUL vs.
85.3% for ESWL, while there was a significant difference
in the treatment effect on stones 10 mm or larger, with
a stone-free rate of 76.8% for TUL vs. 35.2% for ESWL.
They stated that laser TUL was superior to ESWL for
the treatment of stones 10 mm or larger. In our study,
h o w e v e r ,a l ls u b j e c t sw i t hs t o n e s1 0m mo rl a r g e r
achieved a stone-free status. This may be attributable to
our new measures: we usually place patients in the con-
tralateral prone position to potentiate the treatment
effect on lower ureteral stones, in accordance with the
report by Köse et al. [12], and before ultrasonography
we also apply jelly in a thin layer to the skin surface and
to the area on the treatment table around the spot in
contact with the skin to avoid exposure to air, thereby
reducing minute air bubbles generated from the skin
surface and minimizing attenuation of shock waves.
ESWL seems to be an effective first-line treatment also
in subjects who have lower ureteral stones 10 mm or
larger but do not wish to undergo TUL, but it is some-
times difficult to treat stones greater than 10 mm by
ESWL monotherapy. So, it is necessary to perform
ESWL and TUL combination therapy. In contrast, these
subjects with X-ray-negative stones underwent intrave-
nous pyelography (IVP) and ureteral catheter insertion
in combination with ESWL. These patients of ours had
a stone-free status with only ESWL therapy.
Madbouly et al. [13] recently reported that the treat-
ment effect of ESWL with the Lithostar Multiline per-
formed under general anesthesia was significantly
greater when shock waves were delivered at a slow rate
(60/min) than at a rapid rate (120/min), with an efficacy
rate of 98.7% vs. 90.0%. Pace et al. [14] and Peterson et
al. [15] also reported similar results. Thus, ESWL treat-
ment should be performed at a slow rate in the future.
Complications of ESWL include renal subcapsular
hematoma, the incidence of which has been reported to
be between 0.078% and 0.6% [1,16], and has also been
reported to increase up to 32% as a result of perfor-
mance of postoperative routine CT and MRI [17]. Risk
factors for renal subcapsular hematoma are reported to
be 1) hypertension, 2) coagulopathy, and 3) previous
ESWL therapy [18]. In our study, renal subcapsular
hematoma occurred in one subject. This subject had a
history of hypertension, which may have caused this
complication.
Conclusions
ESWL with the Sonolith vision manufactured by EDAP
produced a treatment effect equivalent to those achieved
with other models of ESWL equipment. ESWL seems to
be an effective first-line treatment also in patients who
Table 3 Treatment results by location
1 month 3 months
Site No of pts Stone-free rate Efficacy rate Stone-free rate Efficacy rate
Middle renal 52 53.80% 69.20% 71.20% 78.80%
Lower renal 10 20.00% 40.00% 60.00% 70.00%
Total (renal) 62 48.40% 64.50% 69.40% 77.40%
Upper ureteral 113 73.50% 83.20% 89.40% 92.00%
Middle ureteral 14 64.30% 71.40% 100% 100%
Lower ureteral 37 64.90% 75.70% 94.60% 94.60%
Total (ureteral) 164 70.70% 80.50% 91.50% 93.30%
Table 4 Treatment results by model
White et al. Johnson et al. Egilmez et al Nomikos et al. Our institute
Manufacturer Dornier Dornier Siemens EDAP EDAP
Model Delta lithotriptor Delta S lithotriptor Lithostar Sonolith vision Sonolith vision
No. of cases 5735 270 2670 309 226
Location of Stone kidney/ureter kidney/ureter kidney/ureter kidney kidney/ureter
Stone-free rate (%) 58.5 73.3 79 75 85.4
Eficacy rate (%) 85.1 85.6 88.9
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wish to undergo TUL, if measures such as suitable posi-
tioning of patients during treatment are taken.
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